Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$993.1M
39M shares
52-week range
$18.80 – $27.64
74% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $337.3M | $421.0M | $429.6M | $541.5M | $666.8M | $675.0M | $701.0M | $726.4M |
| Cost of revenue | $86.8M | $106.7M | $117.3M | $140.3M | $199.3M | $184.7M | $170.4M | $149.7M |
| Gross profit | $250.4M | $314.3M | $312.3M | $401.3M | $467.5M | $490.3M | $530.5M | $576.7M |
| Gross margin | 74.3% | 74.7% | 72.7% | 74.1% | 70.1% | 72.6% | 75.7% | 79.4% |
| R&D | $55.7M | $72.1M | $59.4M | $55.5M | $84.8M | $76.3M | $81.6M | $117.3M |
| Operating income | $15.9M | $10.5M | $46.4M | $89.9M | $60.0M | $87.7M | −$73.4M | $33.3M |
| EBITDA | $33.1M | $30.7M | $63.5M | $113.9M | $140.4M | $154.6M | $29.1M | $122.5M |
| Net income | −$471.0K | −$11.0M | $145.5M | $42.0M | $15.9M | $42.0M | −$99.6M | $7.0M |
| Net margin | -0.1% | -2.6% | 33.9% | 7.8% | 2.4% | 6.2% | -14.2% | 1.0% |
| EPS (diluted) | -0.01 | -0.27 | 3.33 | 0.92 | 0.34 | 0.89 | -2.15 | 0.16 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $768M | $2.88 | $2.79–$2.97 | 3 |
| 2027 | $831M | $3.61 | $3.30–$3.92 | 3 |
| 2028 | $954M | $4.85 | $4.80–$4.88 | 1 |
| 2029 | $925M | $4.89 | $4.84–$4.92 | 1 |
Forward consensus · source: Financial Modeling Prep
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
www.pacira.comNo one on the platform currently holds PCRX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,825,501 | $41.3M |
No one on the platform has traded PCRX yet.
| $2.1B |
| — |
| MNMDMind Medicine (MindMed) Inc. | $20.69 | +0.44% | $1.6B | — |
| OCSOculis Holding AG | $13.87 | +5.96% | $793M | — |
Source: Financial Modeling Prep · peers by sector/industry
$PCRX reddest day in a while and we are green - how backwards is this stock?
View on StockTwits ↗$PCRX greenest day of the year and this is Red…fitting and expected
View on StockTwits ↗$PCRX Share Price: $23.10 Contract Selected: Nov 20, 2026 $25 Calls Buy Zone: $2.76 – $3.41 Target Zone: $4.46 – $5.46 Potential Upside: 53% ROI Time to Expiration: 189 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$PCRX for a year this has been the PERFECT channel trade. Buy at $21 sell at $26 over and over and over. Money.
View on StockTwits ↗$PCRX reported 0.60 EPS and 177.38 revenue for Q1. http://www.estimize.com/intro/pcrx?chart=historical&metric_name=eps&utm_content=PCRX&utm
View on StockTwits ↗$PCRX Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.07 down -30.00% YoY • Reported revenue of $177.38M up 5.00% YoY
View on StockTwits ↗What Happens During Surgery May Reduce Opioid Use for Months: https://jlsfund.substack.com/p/what-happens-during-surgery-may-reduce $PCRX
View on StockTwits ↗$PCRX Dam, going down w/health care. Low basis so not near my stop...yet.
View on StockTwits ↗Wall St is expecting 0.55 EPS for $PCRX Q1 [Reporting 04/30 AMC] http://www.estimize.com/intro/pcrx?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗$HRTX 2026 Bull Case & M&A Signal 1️⃣ VALUATION: Market Cap ~$150M vs $173M-$183M 2026 Rev Guidance. Trading <0.9x Sales (Biotech avg 3x-5x). 2️⃣ THE TAX TREASURE (NOL): $1.37B in Net Operating Losses = ~$288M real tax savings (at 21% rate). THE TAX CREDIT ALONE IS WORTH 2X THE MARKET CAP. Buyer pays "less than zero" for operations. 3️⃣ NOPAIN ACT: Zynrelef now reimbursed outside the bundle (ASP + 6%). Hospitals PROFIT from using it. J-Code assigned = seamless billing. Non-opioid shift is the huge tailwind. 4️⃣ OWNERSHIP & DEFENSE: 80%+ Institutional (Rubric 15.9%, Clearline Capitale 6.49%, Adage 6.1%). NOL shielding: Poison Pill at 4.99% prevents hostile takeovers, preserving tax value for a friendly M&A. 5️⃣ THE CLUE: April 6, 2026 SEC 8-K updated CEO Golden Parachute (200% salary + equity vesting on acquisition). Company is clearly being dressed for sale to the highest bidder ($PCRX or Big Pharma). Short Interest 27.5% | DTC ~30 days, massive squeeze potential on any catalyst.
View on StockTwits ↗Wall St is expecting 0.61 EPS for $PCRX Q1 [Reporting 05/06 AMC] http://www.estimize.com/intro/pcrx?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗$PCRX I would really like to know who’s buying this cow dung of a stock.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Trading at NaN× earnings vs its 106.8× historical median P/E.
Fair value ≈ $-243.52 · price $25.37 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.